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Abstract
Background: Recent evidence suggests that there is often substantial variation in the benefits and harms across a
trial population. We aimed to identify regression modeling approaches that assess heterogeneity of treatment effect
within a randomized clinical trial.
Methods: We performed a literature review using a broad search strategy, complemented by suggestions of a
technical expert panel.
Results: The approaches are classified into 3 categories: 1) Risk-based methods (11 papers) use only prognostic factors
to define patient subgroups, relying on the mathematical dependency of the absolute risk difference on baseline risk;
2) Treatment effect modeling methods (9 papers) use both prognostic factors and treatment effect modifiers to
explore characteristics that interact with the effects of therapy on a relative scale. These methods couple data-driven
subgroup identification with approaches to prevent overfitting, such as penalization or use of separate data sets for
subgroup identification and effect estimation. 3) Optimal treatment regime methods (12 papers) focus primarily on
treatment effect modifiers to classify the trial population into those who benefit from treatment and those who do not.
Finally, we also identified papers which describe model evaluation methods (4 papers).
Conclusions: Three classes of approaches were identified to assess heterogeneity of treatment effect. Methodological
research, including both simulations and empirical evaluations, is required to compare the available methods in
different settings and to derive well-informed guidance for their application in RCT analysis.
Introduction
Evidence based medicine (EBM) has heavily influenced
the standards of current medical practice. Randomized
clinical trials (RCTs) and meta-analyses of RCTs are
regarded as the gold standards for determining the com-
parative efficacy or effectiveness of two (or more) treat-
ments within the EBM framework. Within this
framework, as described in Guyatt et al’s classic User’s
Guide to the Medical Literature II [1], “if the patient
meets all the [trial] inclusion criteria, and doesn’t violate
any of the exclusion criteria—there is little question that
the results [of the trial] are applicable”. It has thus been
argued that RCTs should attempt to include even
broader populations to ensure generalizability of their
results to more (and more diverse) individuals [2, 3].
However, generalizability of an RCT result and applic-
ability to a specific patient move in opposite directions
[4, 5]. When trial enrollees differ from one another in
many observed determinants of the outcome of interest
(both primary and safety), it can be unclear to whom the
overall average benefit-harm trade-offs actually apply—
even among those included in the trial [6, 7]. Precision
medicine aims to target the appropriate treatment to the
appropriate patients. As such, analysis of heterogeneity
of treatment effect (HTE), i.e. non-random variation in
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the direction or magnitude of a treatment effect for sub-
groups within a population [8], is the cornerstone of pre-
cision medicine; its goal is to predict the optimal
treatments at the individual level, accounting for an indi-
vidual’s risk for harm and benefit outcomes.
In this scoping review [9], we aim to identify and
categorize the variety of regression-based approaches for
predictive heterogeneity of treatment effects analysis.
Predictive approaches to HTE analyses are those that
provide individualized predictions of potential outcomes
in a particular patient with one intervention versus an
alternative or, alternatively, that can predict which of 2
or more treatments will be better for a particular patient,
taking into account multiple relevant patient characteris-
tics. We distinguish these analyses from the typical one-
variable-at-a-time subgroup analyses that appear in for-
est plots of most major trial reports, and from other
HTE analyses which explore or confirm hypotheses re-
garding whether a specific covariate or biomarker modi-
fies the effects of therapy. To guide future work on
individualizing treatment decisions, we aimed to
summarize the methodological literature on regression
modeling approaches to predictive HTE analysis.
Methods
The terminology in this scoping review hews closely to that
in the PATH Statement and PATH Statement Explanation
and Elaboration articles, and we refer readers to these papers
for details. Generally, we use the term HTE to refer to a
scale-dependent property. This is in distinction to other
writers that have reserved the term HTE to refer specifically
to heterogeneity on a relative scale [10]. Thus, when out-
come risk varies across subgroups of patients, HTE must
exist on some scale. If relative risk is constant, then there is
HTE on the clinically important absolute scale. Nevertheless,
since this review focuses on regression methods which are
typically performed on the odds or hazard ratio scales, when
we use the terms “effect modifier” and “effect modification”
and “statistical interaction”, we are generally referring to ef-
fect modification on a relative scale (e.g. hazard ratio or odds
ratio), unless we otherwise specify—although we recognize
that these too are scale dependent concepts [11–15]. Add-
itionally, we note that we generally eschew the term “individ-
ual treatment effects”, since person level effects cannot be
observed or measured in parallel arm clinical trials (owing to
the fundamental problem of causal inference, only one coun-
terfactual outcome can be observed in a given patient).
Nevertheless, the common goal of the different methods of
predictive approaches to HTE we describe herein is to pro-
vide “individualized” treatment effect estimates from group-
based data, since medical decisions are generally made at the
individual person level [14]. These treatment effects are
estimated conditional on many covariates, which are felt to
be relevant for determining the benefits of therapy.
Due to the absence of medical subject headings (MeSH)
for HTE, we used a relatively broad search strategy to
maximize sensitivity. For the time period 1/1/2000
through 8/9/2018, we searched Medline and Cochrane
Central using the text word search strategy from Table 1.
We also retrieved seminal articles suggested by a technical
expert panel (TEP). The TEP was comprised of 16 experts
who represented various perspectives on predictive HTE
analyses, including expertise in HTE, prediction modeling,
clinical trials, and guideline development as well as a pa-
tient advocate. More details on the TEP are available in
the PATH Statement [12, 13].
We sought papers that developed or evaluated methods
for predictive HTE in the setting of parallel arm RCT de-
signs or simulated RCT. Abstracts were screened to iden-
tify papers that developed or evaluated a regression-based
method for predictive HTE on actual or simulated parallel
arm RCT data. Papers describing a generic approach that
could be applied using either regression or non-regression
methods, or papers comparing regression to non-
regression methods were also included. Similarly, papers
comparing generic one-variable-at-a-time approaches to
predictive HTE methods were also included. Finally, pa-
pers suggested by the TEP that fell outside the search win-
dow were considered for inclusion.
Table 1 Search strategy for the study
# Results
1 ((heterogen$ and effect$) or (effect and modif$)).tw.
2 regression.tw.
3 treatment$.tw.
4 (treatment adj1 effect$).tw.
5 (treatment adj1 difference$).tw.
6 exp risk/ or risk.tw.
7 3 or 4 or 5 or 6
8 *Models, Statistical/
9 *Randomized Controlled Trials as Topic/mt
10 Multicenter Studies as Topic/mt
11 *Randomized Controlled Trials as Topic/sn
12 Multicenter Studies as Topic/sn
13 *Clinical Trials as Topic/sn
14 *Precision Medicine/mt
15 or/8–14
16 1 and 2
17 2 and 7
18 15 and 17
19 15 and 16
20 18 or 19
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We excluded papers solely related to cross-over,
single-arm, and observational study designs. We also ex-
cluded papers that were primarily applications of exist-
ing methods, such as those that primarily aim to
estimate a treatment effect of interest in a specific pa-
tient population, rather than papers with the primary
aim of developing or evaluating methods of predictive
HTE. We also excluded papers using only non-
regression-based methods. Similarly, methods papers
about ONLY non-predictive subgroup analysis, i.e. one-
variable-at-a-time or conventional subgroups, were
omitted. We excluded papers on trial enrichment or
adaptive trial designs along with those that use predict-
ive HTE approaches in the design. We also excluded pa-
pers primarily aiming at characterization or
identification of heterogeneity in response rather than
trying to predict responses for individual patients or sub-
sets of patients; e.g. group based trajectory or growth
mixture modeling. Papers on regression methods that
make use of covariates post-baseline, or temporally
downstream of the treatment decision were omitted. Re-
view articles and primarily conceptual papers without
accompanying methods development were also
excluded.
Titles, abstracts and full texts were retrieved and
double-screened by six independent reviewers against
eligibility criteria. Disagreements were resolved by group
consensus in consultation with a seventh senior expert
reviewer (DMK) in meetings.
Results
We identified 2510 abstracts that were screened in du-
plicate. We retrieved 64 full-text articles and an add-
itional 110 suggested by experts and identified from
reference lists of eligible articles. These 174 full-text arti-
cles were again screened in duplicate with group consen-
sus resolution of conflicts in meetings. A total of 36
articles met eligibility criteria (Fig. 1).
Categorization methods
We could classify all regression-based methods to pre-
dictive HTE into 3 broad categories based on whether
and how they incorporated prognostic variables and
relative treatment effect modifiers:
 Risk-based methods exploit the mathematical
dependency of treatment benefit on a patient’s
baseline risk for the outcome under study [8, 9].
Even though relative treatment effect may vary
across different levels of baseline risk, relative
treatment effect modification by each covariate is
not considered, i.e. no covariate by treatment
interaction terms are considered (Table 2, eqs. 1–3).
Fig. 1 Study flow chart
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 Treatment effect modeling methods use both the
main effects of risk factors and covariate-by-
treatment interaction terms (on the relative scale) to
estimate individualized benefits. They can be used
either for making individualized absolute benefit pre-
dictions or for defining patient subgroups with simi-
lar expected treatment benefits (Table 2, eq. 4).
 Optimal treatment regime methods focus
primarily on treatment effect modifiers (covariate by
treatment interactions) for the definition of a treatment
assignment rule dividing the trial population into those
who benefit from treatment and those who do not
(Table 2, eq. 5). Contrary to previous methods, baseline
risk or the magnitude of absolute treatment benefit are
not of primary concern.
Although risk-based methods emerged earlier (Fig. 2),
methodology papers on treatment effect modeling (9 pa-
pers) and optimal treatment regimes (12 papers) are
more frequently published since 2010 than papers on
risk-based methods (8 papers). Even though extensive
literature exists on model evaluation when it comes to
prediction modeling, the same task can be quite challen-
ging when modeling treatment effects [16]. That is due
to the unavailability of counterfactual outcomes under
the alternative treatment, providing a substantial chal-
lenge to the assessment of model fit. Methods included
in the review concerning model evaluation in the setting
of predictive HTE (4 papers) were assigned to a separate
category as they are relevant to all identified approaches.
Risk-based methods
The most rigid and straightforward risk-based methods
assume a constant relative treatment effect across differ-
ent levels of baseline risk and ignore potential interac-
tions with treatment. Dorresteijn et al. [17] studied
individualized treatment with rosuvastatin for prevention
of cardiovascular events. They combined existing predic-
tion models (Framingham score, Reynolds risk score)
with the average rosuvastatin effect found in an RCT. To
obtain individualized absolute treatment benefits, they
multiplied baseline risk predictions with the average risk
reduction found in trials. The value of the proposed ap-
proach is assessed in terms of improved decision making
by comparing the net benefit with treat-none and treat-
all strategies [18]. Julien and Hanley [19] estimated prog-
nostic effects and treatment effect directly form trial data,
by incorporating a constant relative treatment effect term
in a Cox regression model. Patient-specific benefit predic-
tions followed from the difference between event-free sur-
vival predictions for patients with and without treatment.
A similar approach was used to obtain the predicted 30-
day survival benefit of treatment with aggressive thromb-
olysis after acute myocardial infarction [20].
Risk stratification approaches analyze relative treatment
effects and absolute treatment effects within strata of pre-
dicted risk, rather than assuming a constant relative effect.
Both Hayward et al. [21] and Iwashyna et al. [22] demon-
strated that these methods are useful in the presence of
treatment-related harms to identify patients who do not
benefit (or receive net harm) from a treatment that is
beneficial on average. In a range of plausible scenarios
evaluating HTE when considering binary endpoints, simu-
lations showed that studies were generally underpowered
to detect covariate-by-treatment interactions, but ad-
equately powered to detect risk-by-treatment interactions,
even when a moderately performing prediction model was
used to stratify patients. Hence, risk stratification methods
can detect patient subgroups that have net harm even
when conventional methods conclude consistency of ef-
fects across all major subgroups.
Kent et al. [23] proposed a framework for HTE
analysis in RCT data that recommended published
trials routinely report the distribution of baseline
risk in the overall study population and in the sep-
arate treatment arms using a risk prediction tool.
Primarily binary or time-to-event outcomes were
considered. Researchers should demonstrate how
Table 2 Equations corresponding to treatment effect heterogeneity assessment methods
Risk modeling
A multivariate regression model f that predicts the risk of an outcome y based on the predictors x1…, xp is identified or developed:
riskðx1;…; xpÞ ¼ Efyjx1;…xpg ¼ f ðαþ β1x1 þ…βpxpÞ ð1Þ
The expected outcome of a patient with measured predictors x1, …, xp receiving treatment T (where T = 1, when patient is treated and 0 otherwise)
based on the linear predictor lp(x1,…xp) = a + β1x1 +…βpxp from a previously derived risk model can be described as:
Efyjx1;…; xp; Tg ¼ f ðlpþ γ0T þ γT lpÞ ð2Þ
When the assumption of constant relative treatment effect across the entire risk distribution is made (risk magnification), equation (2) takes the form:
Efyjx1;…; xp; Tg ¼ f ðlpþ γ0TÞ ð3Þ
Treatment effect modeling
The expected outcome of a patient with measured predictors x1, …, xp receiving treatment T can be derived from a model containing predictor
main effects and potential treatment interaction terms:
Efyjx1;…; xp; Tg ¼ f ðαþ β1x1 þ⋯þ βpxp þ γ0T þ γ1Tx1 þ⋯þ γpTxpÞ ð4Þ
Optimal treatment regime
A treatment regime T(x1,…, xp) is a binary treatment assignment rule based on measured predictors. The optimal treatment regime maximizes the
overall expected outcome across the entire target population:
Toptimal ¼ argmaxT EfEfyjx1;…xp; Tðx1;…; xpÞgg ð5Þ
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relative and absolute risk reduction vary by baseline
risk and test for HTE with interaction tests. Exter-
nally validated prediction models should be used,
when available.
In the absence of an adequate prediction model when
performing a risk-based assessment of HTE, an internal
risk model from the data at hand can be derived. Burke
et al. [24] demonstrated that developing the risk model
on the control arm of the trial may result in overfitting
and, thus, exaggerate the presence of HTE. In extensive
simulations, internally developed prediction models
blinded to treatment assignment led to unbiased treat-
ment effect estimates in strata of predicted risk. Using
this approach to re-analyze 32 large RCT, Kent et al.
[25] demonstrated that variation in the outcome risk
within an RCT is very common, in the presence of ad-
equately performing prediction models, which in turn
leads to substantial HTE on the clinically important
scale of absolute risk difference. Several trials from this
analysis had clinically relevant results [26–28].
Similar to Burke et al. [24], Abadie et al. [29] pre-
sented evidence of large biases in risk stratified assess-
ment of HTE in two randomized experiments rising
from the development of a prediction model solely from
the control arm. They focused on financial outcomes
that are primarily continuous. As a remedy, they consid-
ered both a leave-one-out approach, where individual-
ized risk predictions are obtained from a model derived
by excluding the particular individual, and a repeated
split sample approach, where the original sample is re-
peatedly split into a sample for the development of the
prediction model and a sample for treatment effect esti-
mation within risk strata. These approaches were found
to substantially reduce bias in a simulation study. Finally,
Groenwold et al. [30] found in simulations that the in-
clusion of a constant relative treatment effect in the de-
velopment of a prediction model better calibrates
predictions to the untreated population. However, this
approach may not be optimal for risk-based assessment
of HTE, where accurate ranking of risk predictions is of
primary importance for the calibration of treatment
benefit predictions.
Follmann and Proschan [31] proposed a one-step like-
lihood ratio test procedure based on a proportional in-
teractions model to decide whether treatment interacts
with a linear combination of baseline covariates. Their
Fig. 2 Publications included in the review from 1999 until 2019. Numbers inside the bars indicate the method-specific number of publications
made in a specific year
Rekkas et al. BMC Medical Research Methodology          (2020) 20:264 Page 5 of 12
proportional interactions model assumes that the effects
of prognostic factors in the treatment arm are equal to
their effects in the control arm multiplied by a constant,
the proportionality factor. Testing for an interaction
along the linear predictor amounts to testing that the
proportionality factor is equal to 1. If high risk patients
benefit more from treatment (on the relative scale) and
disease severity is determined by a variety of prognostic
factors, the proposed test results in greater power to de-
tect HTE on the relative scale compared to multiplicity-
corrected subgroup analyses. Even though the proposed
test requires a continuous response, it can be readily im-
plemented in large clinical trials with binary or time-to-
event endpoints.
Kovalchik et al. [32] expanded upon the previous ap-
proach by exploring misspecification of the proportional
interactions model, when considering a fixed set of pre-
specified candidate effect modifiers. A proportional inter-
actions model is misspecified either when covariates with
truly proportional effects are excluded or when covariates
with non-proportional effects across treatment arms are
included in the model. In this case the one-step likelihood
ratio test of Follmann and Proschan [31] fails to achieve
its statistical advantages. For model selection an all subsets
approach combined with a modified Bonferroni correction
method can be used. This approach accounts for correl-
ation among nested subsets of considered proportional in-
teractions models, thus allowing the assessment of all
possible proportional interactions models while control-
ling for the familywise error rate.
Treatment effect modeling
Using data from the SYNTAX trial [33] Van Klaveren
et al. [34] considered models of increasing complexity
for the prediction of HTE using data from the SYNTAX
trial. They compared different Cox regression models
for the prediction of treatment benefit: 1) a model with-
out any risk factors; 2) a model with risk factors and a
constant relative treatment effect; 3) a model with treat-
ment, a prognostic index and their interaction; and 4) a
model including treatment interactions with all available
prognostic factors, fitted both with conventional and
with penalized ridge regression. Benefit predictions at
the individual level were highly dependent on the model-
ing strategy, with treatment interactions improving treat-
ment recommendations under certain circumstances.
Basu et al. [35] developed and validated risk models
for predicting the absolute benefit (reduction of time to
CVD events) and harm (serious adverse events) from in-
tensive blood pressure therapy, using data from SPRINT.
They compared traditional backward selection to an
elastic net approach for selection and estimation of all
treatment-covariate interactions. The two approaches se-
lected different treatment-covariate interactions and—
while their performance in terms of CVD risk prediction
was comparable when externally validated in the AC-
CORD BP trial [36]—the traditional approach performed
considerably worse than the penalized approach when
predicting absolute treatment benefit. However, with re-
gard to selection of treatment interactions, Ternes et al.
[37] concluded from an extensive simulation study that
no single methodology yielded uniformly superior per-
formance. They compared 12 different approaches in a
high-dimensional setting with survival outcomes. Their
methods ranged from a straightforward univariate ap-
proach as a baseline, where Wald tests accounting for
multiple testing were performed for each treatment-
covariate interaction to different approaches for dealing
with hierarchy of effects—whether they enforce the in-
clusion of the respective main effects if an interaction is
selected—and also different magnitude of penalization of
main and interaction effects.
Another approach to reducing overfitting of treatment
effect models is separation of treatment effect estimation
from subgroup identification. Cai et al. [38] fit “working”
regression parametric models within treatment arms to
derive absolute treatment benefit scores initially. In a
second stage, the population is stratified into small
groups with similar predicted benefits based on the first-
stage scores. A non-parametric local likelihood approach
is used to provide a smooth estimate of absolute treat-
ment benefit across the range of the derived sores. The
authors focused on continuous and binary endpoints,
but their method can be extended to time-to-event out-
comes. Claggett et al. [39] extended this two-stage meth-
odology to RCTs with multiple outcomes, by assigning
outcomes into meaningful ordinal categories. Overfitting
can be avoided by randomly splitting the sample into two
parts; the first part is used to select and fit ordinal regres-
sion models in both the treatment and the control arm. In
the second part, the models that perform best in terms of
a cross-validated estimate of concordance between pre-
dicted and unobservable true treatment difference— de-
fined as the difference in probability of observing a worse
outcome under control compared to treatment and the
probability of observing a worse outcome under treatment
compared to control—are used to define treatment benefit
scores for patients. Treatment effects conditional on the
treatment benefit score are then estimated through a non-
parametric kernel estimation procedure.
Zhao et al. [40] proposed a two-stage methodology
similar to the approach of Cai et al. [32], focusing on the
identification of a subgroup that benefits from treat-
ment. They repeatedly split the sample population based
on the first-stage treatment benefit scores and estimate
the treatment effect in subgroups above different thresh-
olds. These estimates are plotted against the score
thresholds to assess the adequacy of the selected scoring
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rule. This method could also be used for the evaluation
of different modeling strategies by selecting the one that
identifies the largest subgroup with an effect estimate
above a desired threshold.
Künzel et al. [41] proposed an “X-learner” for settings
where one treatment arm is substantially larger than the
alternative. They also start by fitting separate outcome
models within treatment arms. However, rather than
using these models to calculate treatment benefit scores,
they imputed individualized absolute treatment effects,
defined as the difference between the observed outcomes
and the expected counterfactual (potential) outcomes
based on model predictions. In a second stage, two sep-
arate regression models—one in each treatment arm—
are fitted to the imputed treatment effects. Finally, they
combined these two regression models for a particular
covariate pattern by taking a weighted average of the ex-
pected treatment effects.
Most effect modeling methods start with outcome pre-
dictions conditional on treatment and then examine the
difference in predictions with and without treatment. In
contrast, Weisberg and Pontes [42] introduced a causal
difference outcome variable (“cadit”) which can be mod-
eled directly. In case of a binary outcome, the binary
cadit is 1 when a treated patient has a good outcome or
when an untreated patient does not, and 0 otherwise.
Thus, the dependent variable implicitly codes treatment
assignment and outcome simultaneously. They first
demonstrated that the absolute treatment benefit equals
2 × P(cadit = 1) − 1 and then they derived patient-specific
treatment effect estimates by fitting a logistic regression
model to the cadit. A similar approach was described for
continuous outcomes with the continuous cadit defined
as − 2 and 2 times the centered outcome, i.e. the out-
come minus the overall average outcome, for untreated
and treated patients, respectively.
Finally, Berger et al. [43] proposed a Bayesian method-
ology for the detection of subgroup treatment effects in
case of a continuous response and binary covariates. The
approach identifies single covariates likely to modify
treatment effect, along with the expected individualized
treatment effect. The authors also extended their meth-
odology to include two covariates simultaneously, allow-
ing for the assessment of multivariate subgroups.
Optimal treatment regime methods
A treatment regime (TR) is a function mapping each pa-
tient’s covariate pattern to a single treatment assign-
ment. Any candidate TR can be evaluated based on its
value, i.e. the expected outcome at the population level
if the specific TR were to be followed. The TR achieving
the highest value among all possible TRs is the optimal
treatment regime (OTR). The majority of such methods
follows a two-stage approach, where an outcome
model—usually including treatment interactions—is
used to derive expected treatment benefit in the first
stage. In the second stage treatment assignment is opti-
mized based on the expected outcome. Qian and Mur-
phy [44] advocated a first-stage model including all
covariate main effects and treatment interactions in
combination with LASSO-penalization to reduce model
complexity. Real-valued (continuous or binary) are con-
sidered without considering censoring.
When the outcome model is misspecified, however,
the approach of Qian and Murphy may fail to identify
the best possible treatment regime. As Zhang et al. [45]
introduced an approach robust to such misspecifications
that uses an augmented inverse probability weighted es-
timator of the value function. This is achieved by impos-
ing a missing data framework, where the response under
any candidate OTR is observed if the proposed treat-
ment coincides with actual treatment and is considered
missing otherwise. However, in commenting on this
work, Taylor et al. [46] noted that the misspecification
issues of the outcome models considered in the simula-
tion study presented by Zhang et al. would have been
easily spotted, if common approaches for the assessment
of model fit had been examined. They argue that if ad-
equately fitting outcome models had been thoroughly
sought, the extra modeling required for the robust
methods of Zhang et al. may not have been necessary.
Zhang et al. [47] proposed a novel framework for the
derivation of OTRs for real-valued responses (continu-
ous or binary), within which treatment assignment is
viewed as a classification problem. The OTR is derived
in two separate steps. In the first step, a contrast func-
tion is estimated, determining the difference between ex-
pected outcomes under different treatment assignments
for each individual patient. The sign of the contrast
function is then used to define class labels, i.e. -1 for
negative contrast (harm) and + 1 for positive contrast
(benefit). In the second step, any classification technique
can be used to find the OTR by minimizing the expected
misclassification error weighted by the absolute contrast.
The authors demonstrated that many of the already
existing OTR methods [44, 45] fit within their frame-
work by defining a specific contrast function.
When the outcome of interest is continuous, the mag-
nitude of absolute treatment benefit estimates derived
from regression-based methods depends solely on treat-
ment interactions. Therefore, Foster et al. [48] focus on
non-parametric estimation of the function defining the
structure of treatment-covariate interactions for a con-
tinuous outcome of interest. More specifically, they re-
cursively update non-parametric estimates of the
treatment-covariate interaction function from baseline
risk estimates and vice-versa until convergence. The esti-
mates of absolute treatment benefit are then used to
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restrict treatment to a contiguous sub-region of the co-
variate space.
Xu et al. [49] claimed that the identification of an
OTR with high value depends on the adequate assess-
ment of the sign of treatment-covariate interactions ra-
ther than on the estimation of the contrast function.
They demonstrated that in many common cases (binary
or time-to-event outcomes), even though the underlying
structure of interactions can be quite complex, its sign
can be approximated from a much simpler linear func-
tion of effect modifiers. Using the classification frame-
work of Zhang et al. [47], they assign patients to class
labels based on the resulting sign from these candidate
linear combinations. The coefficients of that linear func-
tion are derived by minimizing the misclassification
error weighted by the observed outcome—assuming
higher values are preferable. In this way, the derived
OTR is forced to contradict actual treatment assignment
when the observed outcome is low. Tian et al. [50] pro-
posed a different approach that solely focuses on
treatment-covariate interactions by recoding the binary
treatment indicator variable to − 1/2 for control patients
and + 1/2 for treated patients and multiplying it with the
covariates of a posited regression model to derive modi-
fied covariates so that the linear predictor of the model
predicting the outcome from the modified covariates
can be used as a score for stratifying patients with regard
to treatment benefits. Starting from continuous re-
sponses they generalized their methodology to binary
and time-to-event outcomes.
Kraemer [51] suggested a methodology that implicitly
assesses treatment-covariate interactions using the cor-
relation coefficient of the pairwise difference of the con-
tinuous outcome between treatment arms and their
respective candidate predictive factor pairwise difference
as a measure of effect modification. A stronger compos-
ite treatment effect modifier can then be constructed by
fitting a regression model predicting pairwise outcome
differences between treatments from the averages of the
effect modifier values across treatment arms and then
summing the individual effect modifiers weighted by the
estimated regression coefficients. Treatment can then be
assigned based on stratification on the composite treat-
ment effect moderator. Two different approaches to
model selection in Kraemer’s effect modifier combin-
ation method were identified in clinical applications.
Principal component analysis was used to select an un-
correlated subset from a large set of possibly correlated
effect modifiers [52]. Alternatively, the cross-validated
mean squared error of increasingly complex regression
models was used to select the number of effect modifiers
to construct the composite one [53].
Gunter et al. [54] proposed a method for the discovery
of covariates that qualitatively interact with treatment.
Using LASSO regression to reduce the space of all pos-
sible combinations of covariates and their interaction
with treatment to a limited number of covariate subsets,
their approach selects the optimal subset of candidate
covariates by assessing the increase in the expected re-
sponse from assigning based on the considered treat-
ment effect model, versus the expected response of
treating everyone with the treatment found best from
the overall RCT result. The considered criterion also pe-
nalizes models for their size, providing a tradeoff be-
tween model complexity and the increase in expected
response. The method focuses solely on continuous out-
comes, however, suggestions are made on its extension
to binary type of outcomes.
Finally, Petkova et al. [55] proposed to combine base-
line covariates into a single generated effect modifier
(GEM) based on the linear model. The GEM is defined
as the linear combination of candidate effect modifiers
and the objective is to derive their individual weights.
This is done by fitting linear regression models within
treatment arms where the independent variable is a
weighted sum of the baseline covariates, while keeping
the weights constant across treatment arms. The inter-
cepts and slopes of these models along with the individ-
ual covariate GEM contributions are derived by
maximizing the interaction effect in the GEM model, or
by providing the best fit to the data, or by maximizing
the statistical significance of an F-test for the interaction
effects—a combination of the previous two. The authors
derived estimates that can be calculated analytically,
which makes the method easy to implement.
A growing literature exists on estimating the effect of
introducing the OTR to the entire population [56–59].
Luedtke and Van der Laan [56] provide an estimate of
the optimal value—the value of the OTR—that is valid
even when a subset of covariates exists for which treat-
ment is neither beneficial nor harmful. It has been previ-
ously demonstrated that estimation of the optimal value
is quite difficult in those situations [60]. Based on the
proposed method, an upper bound of what can be hoped
for when a treatment rule is introduced can be estab-
lished. In addition, Luedtke and Van der Laan [59] pro-
vided an estimation method for the impact of treating
the optimal subgroup, i.e. the subgroup that is assigned
treatment based on the OTR. Their methodology returns
an estimate of the population level effect of treating
based on the OTR compared to treating no one.
Model evaluation
Schuler et al. [61] defined three broad classes of metrics
relevant to model selection when it comes to treatment
effect modeling. μ-risk metrics evaluate the ability of
models to predict the outcome of interest conditional on
treatment assignment. Treatment effect is either
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explicitly modeled by treatment interactions or implicitly
by developing separate models for each treatment arm.
τ-risk metrics focus directly on absolute treatment bene-
fit. However, since absolute treatment benefit is unob-
servable, it needs to be estimated first. Value-metrics
originate from OTR methods and evaluate the outcome
in patients that were assigned to treatment in concord-
ance with model recommendations.
Vickers et al. [18] suggested a methodology for the
evaluation of models predicting individualized treatment
effects. The method relies on the expression of disease-
related harms and treatment-related harms on the same
scale. The minimum absolute benefit required for a pa-
tient to opt for treatment (treatment threshold) can be
viewed as the ratio of treatment-related harms and harms
from disease-related events, thus providing the required
relationship. Net benefit is then calculated as the differ-
ence between the decrease in the proportion of disease-
related events and the proportion of treated patients
multiplied by the treatment threshold. The latter quantity
can be viewed as harms from treatment translated to the
scale of disease-related harms. Then, the net benefit of a
considered prediction model at a specific treatment
threshold can be derived from a patient-subset where
treatment received is congruent with treatment assigned
based on predicted absolute benefits and the treatment
threshold. The model’s clinical relevance is derived by
comparing its net benefit to the one of a treat-all policy.
Van Klaveren et al. [62] defined a measure of discrim-
ination for treatment effect modeling. A model’s ability
to discriminate between patients with higher or lower
benefits is challenging, since treatment benefits are un-
observable in the individual patient (since only one of
two counterfactual potential outcomes can be observed).
Under the assumption of uncorrelated counterfactual
outcomes, conditional on model covariates, the authors
matched patients from different treatment arms by their
predicted treatment benefit. The difference of the ob-
served outcomes between the matched patient pairs (0,
1: benefit; 0,0 or 1, 1: no effect; 1, 0: harm) acts as a
proxy for the unobservable absolute treatment differ-
ence. The c-statistic for benefit can then be defined on
the basis of this tertiary outcome as the proportion of all
possible pairs of patient pairs in which the patient pair
observed to have greater treatment benefit was predicted
to do so.
Finally, Chen et al. [63] focused on the case when
more than one outcomes—often non-continuous— are
of interest and proposed a Bayesian model selection ap-
proach. Using a latent variable methodology, they link
observed outcomes to unobservable quantities, allowing
for their correlated nature. To perform model selection,
they derive posterior probability estimates of false inclu-
sion or false exclusion in the final model for the
considered covariates. Following the definition of an
outcome-space sub-region that is considered beneficial,
individualized posterior probabilities of belonging to that
beneficial sub-region can be derived as a by-product of
the proposed methodology.
Discussion
We identified 36 methodological papers in recent litera-
ture that describe predictive regression approaches to
HTE analysis in RCT data. These methodological papers
aimed to develop models for predicting individual treat-
ment benefit and could be categorized as follows: 1) risk
modeling (n = 11), in which RCT patients were stratified
or grouped solely on the basis of prognostic models; 2)
effect modeling (n = 9), in which patients are grouped or
stratified by models combining prognostic factors with
factors that modify treatment effects on the relative scale
(effect modifiers); 3) optimal treatment regimes (n = 12),
which seek to classify patients into those who benefit
and those who do not, primarily on the basis of effect
modifiers. Papers on the evaluation of different predict-
ive approaches to HTE (n = 4) were assigned to a separ-
ate category. Of note, we also found literature on the
evaluation of biomarkers for treatment selection, which
did not meet inclusion criteria [64–67].
Risk-based approaches use baseline risk determined by
a multivariate equation to define the reference class of a
patient as the basis for predicting HTE. Two distinct ap-
proaches were identified: 1) risk magnification [10, 68]
assumes constant relative treatment effect across all pa-
tient subgroups, while 2) risk stratification analyzes
treatment effects within strata of predicted risk. This ap-
proach is straightforward to implement, and may pro-
vide adequate assessment of HTE in the absence of
strong prior evidence for potential effect modification.
The approach might better be labeled ‘benefit magnifica-
tion’, since benefit increases by higher baseline risk and
a constant relative risk.
Treatment effect modeling methods focus on predict-
ing the absolute benefit of treatment through the inclu-
sion of treatment-covariate interactions alongside the
main effects of risk factors. However, modeling such in-
teractions can result in serious overfitting of treatment
benefit, especially in the absence of well-established
treatment effect modifiers. Penalization methods such as
LASSO regression, ridge regression or a combination
(elastic net penalization) can be used as a remedy when
predicting treatment benefits in other populations. Sta-
ging approaches starting from—possibly overfitted—
“working” models predicting absolute treatment benefits
that can later be used to calibrate predictions in groups
of similar treatment benefit provide another alternative.
While these approaches should yield well calibrated per-
sonalized effect estimates when data are abundant, it is
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yet unclear how broadly applicable these methods are in
conventionally sized randomized RCTs. Similarly, the
additional discrimination of benefit of these approaches
compared to the less flexible risk modeling approaches
remains uncertain. Simulations and empirical studies
should be informative regarding these questions.
The similarity of OTRs to general classification prob-
lems—finding an optimal dichotomization of the covari-
ates space—enables the implementation of several
existing non-regression-based classification algorithms.
For instance Zhao et al. [69] applied a support vector
machine methodology for the derivation of an OTR for
a binary outcome and was later extended to survival out-
comes [70]. Because prognostic factors do not affect the
sign of the treatment effect, several OTR methods rely
primarily on treatment effect modifiers. However, when
treatments are associated with adverse events or treat-
ment burdens (such as costs) that are not captured in
the primary outcome—as is often the case—estimates of
the magnitude of treatment effect are required to ensure
that only patients above a certain expected net benefit
threshold (i.e. outweighing the harms and burdens of
therapy) are treated. Similarly, these classification
methods do not provide comparable opportunity for in-
corporation of patient values and preferences for shared
decision making which prediction methods do.
While there is an abundance of proposed methodo-
logical approaches, examples of clinical application of
HTE prediction models remain quite rare. This may re-
flect the fact that all these approaches confront the same
fundamental challenges. These challenges include the
unobservability of individual treatment response, the curse
of dimensionality from the large number of covariates, the
lack of prior knowledge about the causal molecular mech-
anisms underlying variation in treatment effects and the
relationship of these mechanism to observable variables,
and the very low power in which to explore interactions.
Because of these challenges there might be very serious
constraints on the usefulness of these methods as a class;
while some methods may be shown to have theoretical ad-
vantages, the practical import of these theoretical advan-
tages may not be ascertainable.
The methods we identified here generally approach the
aforementioned challenges from opposite ends. Relatively
rigid methods, such as risk magnification (in which rela-
tive effect homogeneity is assumed) and risk modeling
(which examines changes in relative effect according to
baselines risk only) deal with dimensionality, low power
and low prior knowledge by restricting the flexibility of
the models that can be built to emphasize the well under-
stood influence of prognosis. Effect modeling approaches
permit more flexible modeling and then subsequently try
to correct for the overfitting that inevitably arises. Based
on theoretical considerations and some simulations, it is
likely that the optimal approach depends on the under-
lying causal structure of the data, which is typically un-
known. It is also likely that the method used to assess
performance may affect which approach is considered op-
timal. For example, recent simulations have favored very
simple approaches when calibration is prioritized, but
more complex approaches when discrimination is priori-
tized—particularly in the presence of true effect modifica-
tion [71]. Finally, it is uncertain whether any of these
approaches will add value to the more conventional EBM
approach of using an overall estimate of the main effect,
or to the risk magnification approach of applying that rela-
tive estimate to a risk model.
We identify several limitations to our study. Because
no MeSH identifying these methods exists, we anticipate
that our search approach likely missed some studies. In
addition, a recently growing literature of other non-
regression based methods that assess predictive HTE in
observational databases [72–74] would have been ex-
cluded. Finally, our review is descriptive and did not
compare the approaches for their ability to predict indi-
vidualized treatment effects or to identify patient sub-
groups with similar expected treatment benefits.
Based on the findings and the limitations of our re-
view, several objectives for future research can be de-
scribed. Optimal approaches to the reduction of
overfitting through penalization need to be determined,
along with optimal measures to evaluate models
intended to predict treatment effect. General principles
to judge the adequacy of sample sizes for predictive ana-
lytic approaches to HTE are required to complement the
previous objectives. Also, methods that simultaneously
predict multiple risk dimensions regarding both primary
outcome risks and treatment-related harms need to be
explored. The current regression-based collection of
methods could be expanded by a review of non-
regression approaches. Methods targeted at the observa-
tional setting need also to be considered. Additionally, a
set of empirical and simulation studies should be per-
formed to evaluate and compare the identified methods
under settings representative of real world trials. The
growing availability of publicly available randomized
clinical trials should support this methodological re-
search [75–77].
In conclusion, we identified a large number of meth-
odological approaches for the assessment of heterogen-
eity of treatment effects in RCTs developed in the past
20 years which we managed to divide into 3 broad cat-
egories. Extensive simulations along with empirical eval-
uations are required to assess those methods’ relative
performance under different settings and to derive well-
informed guidance for their implementation. This may
allow these novel methods to inform clinical practice
and provide decision makers with reliable individualized
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information on the benefits and harms of treatments.
While we documented an exuberance of new methods,
we do note a marked dearth of comparative studies in
the literature. Future research could shed light on advan-
tages and drawbacks of methods in terms of predictive
performance in different settings.
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